SPTA1抗体;SPTA1 Antibody—艾普蒂

+ +

•  

   

     Gel: 6%SDS-PAGE, Lysate: 40 μg, Lane: Mouse heart tissue lysate, Primary antibody: P12792(SPTA1 Antibody) at dilution 1/550, Secondary antibody: Goat anti rabbit IgG at 1/8000 dilution, Exposure time: 20 seconds    

  
  

•  

   

     The image is immunohistochemistry of paraffin-embedded Human gastric cancer tissue using P12792(SPTA1 Antibody) at dilution 1/80. (Original magnification: ×200)    

  
  

The SPTA1 antibody targets the alpha-1 subunit of spectrin, a critical cytoskeletal protein encoded by the *SPTA1* gene. Spectrin forms flexible, tetrameric complexes with beta-spectrin subunits, providing structural support to cell membranes and maintaining cell shape, mechanical stability, and membrane organization. In red blood cells (RBCs), αIβI-spectrin heterodomers are essential for maintaining membrane integrity and deformability. Mutations in *SPTA1* are linked to hereditary hemolytic anemias, including hereditary spherocytosis (HS) and hereditary elliptocytosis (HE), characterized by fragile, abnormally shaped RBCs.

SPTA1 antibodies are widely used in research to investigate spectrin's role in RBC disorders and other conditions. They enable detection of α-spectrin expression levels, localization, and structural abnormalities via techniques like Western blotting, immunofluorescence, and flow cytometry. These antibodies also aid in diagnosing spectrin-deficient anemias by identifying reduced or dysfunctional α-spectrin in patient RBCs. Beyond hematology, SPTA1 antibodies contribute to studies in neurology and muscle biology, as spectrin isoforms are involved in neuronal membrane stability and muscle cell organization. Their applications extend to exploring cancer biology, where altered spectrin expression may influence metastasis or drug resistance.

As tools, SPTA1 antibodies help unravel molecular mechanisms of cytoskeletal disorders and support translational research aimed at therapeutic strategies for spectrin-related diseases.